FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.
What happened
FDA inspected Winder Laboratories' drug manufacturing facility in Winder, Georgia, from July 14 to August 5, 2025. FDA observed equipment with drug residue and oxidized metal that had been released as clean, a nonfunctioning and unqualified metal detector, a metal screw in a sealed bottle, and facility defects such as wall gaps and an unknown brown-yellow material. FDA also said similar CGMP violations were cited in prior inspections.
What FDA found
FDA found drug residue and oxidized metal on manufacturing equipment that the quality unit had documented as clean.
21 CFR 211.67(a) and (b)FDA found the metal detector nonfunctioning and not qualified, and a metal screw in a sealed bottle.
21 CFR 211.67(a) and (b)FDA observed wall gaps, unknown brown-yellow material, a taped ceiling vent, and unfinished walls in manufacturing areas.
21 CFR 211.58FDA said the firm's quality systems are inadequate.
21 CFR parts 210 and 211FDA cited similar CGMP violations at prior inspections in 2018, 2022, and 2023.
FDA said the drug products are adulterated because manufacturing did not meet CGMP.
section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA asks Winder to respond in writing within 15 working days with corrective actions and supporting documents, including independent cleaning assessments, CAPA plans, cleaning validation improvements, equipment qualification, and evidence of facility repairs. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- brands that buy prescription tablets from this contract manufacturer
- pharmacies and patients receiving affected lots
- companies relying on Winder's cleaning and metal-detection controls
This is a summary. Read the original letter on fda.gov.